



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/475,704
				Filing Date	December 30, 1999
				First Named Inventor	BARNETT et al.
				Group Art Unit	1635
				Examiner Name	B. Whiteman
Sheet	1	of	1	Attorney Docket Number	PP001631.0002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
/J.P./	B1	WO	03/004620	A2	Chiron Corporation	01-16-2003	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/J.P./	C1	Haas et al., "CYTOTOXIN T-CELL RESPONSES TO HIV-1 REVERSE TRANSCRIPTASE, INTEGRASE AND PROTEASE," AIDS, 12:1427-1436 (1998).	
/J.P./	C2	Hamajima, et al., "THE COMBINATION OF DNA AND PEPTIDE VACCINES INDUCES STRONG IMMUNITIES AGAINST HIV-1 IN BOTH HUMORAL AND CMI," 11 TH International AIDS Conference, Vancouver, British Columbia, July 7-12; 11:6 (abstract no. Mo.A.151) (1996).	
/J.P./	C3	Kent, et al., "A RECOMBINANT AVIPOXVIRUS HIV-1 VACCINE EXPRESSING INTERFERON-GAMMA IS SAFE AND IMMUNOGENIC IN MACAQUES," Vaccine 18:2250-2256 (2000).	
/J.P./	C4	Williamson, et al., "DESIGNING HIV-1 SUBTYPE C VACCINES FOR SOUTH AFRICA," South African Journal of Science, 96:318-324 (2000).	

Examiner Signature	/Jennifer Pitrak/	Date Considered	08/09/2007
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1631.002	Serial No.: 09/475,704
INFORMATION DISCLOSURE CITATION		Applicants: Barnett <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: December 30, 1999	Group: 1643

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS								
		Document Number	Publ. Date	Country	Class	Subclass	Trans-Yes	lation No
/J.P./	BA	WO 96/09378	03/28/96	PCT				
/J.P./	BB	WO 97/31115	08/28/97	PCT				
	BC							
	BD							
	BE							

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/J.P./	CA	Novitsky <u>et al.</u> , "Molecular Cloning and Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Subtype C: a Set of 23 Full-Length Clones from Botswana" <u>J. Virology</u> 73(5):4427-4432, May, 1999
	CB	
	CC	
	CE	
	CF	
	CG	
	CH	
	CI	
	CJ	
	CK	
	CL	
	CM	
	CQ	

Examiner /Jennifer Pitrak/	Date Considered 08/09/2007
-----------------------------------	-----------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.